INEGY 10 MG80 MG TABLETS

Χώρα: Ισραήλ

Γλώσσα: Αγγλικά

Πηγή: Ministry of Health

Δραστική ουσία:

EZETIMIBE; SIMVASTATIN

Διαθέσιμο από:

MERCK SHARP & DOHME ISRAEL LTD

Φαρμακολογική κατηγορία (ATC):

C10AA01

Φαρμακοτεχνική μορφή:

TABLETS

Σύνθεση:

SIMVASTATIN 80 MG; EZETIMIBE 10 MG

Οδός χορήγησης:

PER OS

Τρόπος διάθεσης:

Required

Κατασκευάζεται από:

MERCK SHARP & DOHME B.V., THE NETHERLANDS

Θεραπευτική ομάδα:

SIMVASTATIN

Θεραπευτική περιοχή:

SIMVASTATIN

Θεραπευτικές ενδείξεις:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Ημερομηνία της άδειας:

2012-04-30